Silica-collagen nanoformulations with extended human growth hormone release

Int J Pharm. 2023 Mar 5:634:122662. doi: 10.1016/j.ijpharm.2023.122662. Epub 2023 Feb 1.

Abstract

Growth hormone deficiency has been treated by the daily administration of recombinant human growth hormone (hGH) for decades. Patient compliance to this treatment is generally incomplete due to challenges including dose frequency and lack of perceived benefits. This stimulates the research on new formulations to reduce the number of periodic administrations. In this study silica nanoparticles and silica-collagen nanocomposites were evaluated for hGH loading and release. Bare nanoparticles showed higher hGH adsorption capacity than thiol- and isobutyl-bearing particles of similar diameters. Monitoring of bound protein conformation changes indicated hGH structure retention when adsorbed on bare silica nanoparticles and suggested no alterations on protein activity. Protein-loaded particles incorporated into collagen matrices (silica-collagen nanocomposites) showed a progressive protein release profile different from the observed for hGH-loaded silica nanoparticles and hGH-loaded collagen matrices. While both the collagen and the silica nanoparticle systems reached a 100 % release after 4 and 7 days respectively, silica-collagen nanocomposites showed a bi-phasic prolonged hGH release reaching approximately an 80 % after 15 days. These findings suggest that biocompatible silica-collagen nanocomposites could be used as vehicles for the prolonged delivery of hGH which could lead to a potential reduction in the number of periodic administrations.

Keywords: Collagen; Human growth hormone; Nanocomposites; Prolonged-release; Silica nanoparticles.

MeSH terms

  • Collagen
  • Drug Compounding
  • Growth Hormone
  • Human Growth Hormone* / chemistry
  • Humans
  • Recombinant Proteins
  • Silicon Dioxide

Substances

  • Human Growth Hormone
  • Silicon Dioxide
  • Collagen
  • Recombinant Proteins
  • Growth Hormone